Skip to content

TARSUS PHARMACEUTICALS, INC.

TARS

CIK 0001819790

← back to feed
Revenue (TTM)
$461.75M
+146.7% YoY Q1 May 2026
Net Income (TTM)
−$65.01M
+42.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.58
+48.2% YoY Q1 May 2026
Gross Margin
96.8%
Q1 May 2026
Operating Margin
-15.0%
Q1 May 2026
Net Margin
-14.1%
Q1 May 2026
Free Cash Flow (TTM)
−$111.98M
Q1 May 2026
Cash
$102.19M
Q1 May 2026
Total Debt
$72.6M
Q1 May 2026
Shares Outstanding
43.02M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings